Notizie e Video - US NASDAQ Azioni - Inglese - Pagina 2

CAMBRIDGE, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that it will report its first quarter 2024 financial results and provide an update on its business and pipeline on Wednesday, May 15, after the market close. The Company does not intend to host a conference...

~ Continued Flight-Testing Progress Approaching Full Transition to Forward Flight of the Company’s Large-Scale Prototype eVTOL Aircraft ~ ~ Dynamic Video Footage of Most Recent Flight Test ~ ~ Continuing Detailed Design of the Full-Scale Cavorite X7 Hybrid eVTOL Aircraft, on Track for Completion and Testing in 2026 ~ TORONTO, May 08, 2024 (GLOBE NEWSWIRE) -- New Horizon Aircraft Ltd. (NASDAQ: HOVR), doing business as Horizon Aircraft (“Horizon” or the “Company”), a leading hybrid...

― Phase 2b ReDUX4 clinical trial indicates improvements in functional, structural, and patient-reported outcomes; findings informed the design and choice of efficacy endpoints in the ongoing Phase 3 clinical trial― ― Topline data for the Phase 3 REACH clinical trial of losmapimod in FSHD expected during 4Q’24― CAMBRIDGE, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. ® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of...

Company generates strong earnings and margins, continued execution of omnichannel strategy Company to Host Conference Call Today at 9 a.m. ET MIAMI, May 08, 2024 (GLOBE NEWSWIRE) -- International Money Express, Inc. (NASDAQ: IMXI) (“Intermex” or the “Company”), one of the nation’s leading omnichannel money transfer services to Latin America and the Caribbean, today reported strong operating results for the first quarter of 2024. Financial performance highlights for the first quarter of...

BEIJING, May 08, 2024 (GLOBE NEWSWIRE) -- Global Mofy Metaverse Limited (the "Company" or "Global Mofy Metaverse") (Nasdaq: GMM), a technology solutions provider engaged in virtual content production and the development of digital assets for use in the broader digital entertainment industry, is leveraging generative AI to transform professional film production with its proprietary platform, Gausspeed, developed by its wholly-owned subsidiary, Gauss AI, in collaboration with Heartdub, a...

BOSTON, May 08, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively modulate disease-specific T cells, announced today that it will deliver two poster presentations at the 20th PEGS Boston Summit , the Essential Protein and Antibody Engineering Summit, being held May 13-17, 2024 in Boston, MA and virtually. Presentation Details Date and Time : Monday, May 13 from 7:00 a.m. – 4:30...

ProQR scientists report for the first time in the ADAR RNA editing field in vivo proof of target engagement (RNA editing) leading to meaningful changes in biomarkers in NHPs using Axiomer™ RNA Editing Oligonucleotides Preclinical proof of concept for the Company’s AX-0810 program targeting NTCP for cholestatic diseases presented at ASGCT Annual Meeting Management webinar May 9, 2024 at 8:00 am EDT LEIDEN, Netherlands & CAMBRIDGE, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV...

Highest Net Revenue Ever Recorded During First Quarter of $295.7 Million Pre-Recorded Earnings Call Webcast Available on Investor Relations Website LAS VEGAS, May 08, 2024 (GLOBE NEWSWIRE) -- HF Foods Group Inc. (NASDAQ: HFFG) (“HF Foods”, or the “Company”), a leading food distributor to Asian restaurants across the United States, reported unaudited financial results for the first quarter ended March 31, 2024. First Quarter 2024 Financial Results Net revenue increased 0.6% to $295.7...

AUSTIN, Texas, May 08, 2024 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira” or the “Company”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced that the Company will report its financial results for the three months ended March 31, 2024, on Wednesday, May 15, 2024. Management will also host a conference call at 8:30 a.m. Eastern Time to discuss financial results and provide a...

SAN DIEGO, May 08, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that the Company’s management will participate in a fireside chat and one-on-one investor meetings at the Citizens JMP Life Sciences Conference, to be held in New York, NY May 13-14, 2024. Format: Fireside chat and scheduled one-on-one...

Microsoft and LinkedIn release the 2024 Work Trend Index on the state of AI at work PR Newswire REDMOND, Wash., May 8, 2024 New data shows most employees are experimenting with AI and growing their skills — now, the job of every leader is to channel this experimentation into business impact REDMOND, Wash. , May 8, 2024 /PRNewswire/ -- On Wednesday, Microsoft Corp. and LinkedIn released the 2024 Work Trend Index, a joint report on the state of AI at work titled, " AI at work is here. Now comes...

Findings demonstrate ability of PM359 to correct disease-causing mutation in CGD patient blood stem cells, leading to restored immune function in vivo with no off-target edits detected IND for PM359 recently cleared by U.S. FDA; data support advancement into Phase 1/2 clinical trial CAMBRIDGE, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated, one-time curative genetic therapies, today...

BioMarin to Present at the BofA Securities 2024 Health Care Conference on Wednesday, May 15 at 10:00am PT / 1:00pm ET, in Las Vegas, NV PR Newswire SAN RAFAEL, Calif., May 8, 2024 SAN RAFAEL, Calif. , May 8, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander Hardy , President, and Chief Executive Officer of BioMarin will present at the BofA Securities 2024 Healthcare Conference on Wednesday, May 15, 2024 , at 10:00am PT / 1:00pm ET , in Las Vegas,...

Icahn Enterprises L.P. (Nasdaq: IEP) Today Announced Its First Quarter 2024 Financial Results PR Newswire Sunny Isles Beach, Fla., May 8, 2024 Sunny Isles Beach, Fla. , May 8, 2024 /PRNewswire/ -- First quarter net loss attributable to IEP of $38 million , an improvement of $232 million over prior year quarter First quarter Adjusted EBITDA attributable to IEP of $134 million , an increase of $39 million over prior year quarter Indicative Net Asset Value was approximately $5 billion as of March...

Lipocine Announces Late Breaking Oral Presentation of Data from the Phase 2 Study of LPCN 1148 at EASL Congress 2024 PR Newswire SALT LAKE CITY, May 8, 2024 SALT LAKE CITY , May 8, 2024 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company, today announced that data from the Phase 2 study of LPCN 1148 has been selected for a late breaking oral presentation at the European Association for the Study of Liver ("EASL") Congress, to take place June 5 to 8, 2024 in Milan, Italy ....

The U.S. medical scientific community is calling for clinical studies to expand shared understanding of babesiosis, an emerging tick-borne illness. The upcoming 60 Degrees Pharma clinical trial of tafenoquine in treating babesiosis will be the first and only such study to date. Enrollment is planned to begin in summer 2024. The Journal of Infectious Diseases has published a letter outlining the planned trial protocol. WASHINGTON, May 08, 2024 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc....

WATERTOWN, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced that management will participate in a fireside chat at the Citizens JMP Life Sciences Conference on Tuesday, May 14th at 11:30 a.m. E.T. To register for the live event, please click here . The webcast will also be available on the Company’s website on the...

WEST CHESTER, Pa., May 08, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that it will host a conference call and live webcast at 8:30 a.m. ET on Monday, May 13, 2024 to provide a corporate update and discuss the Company's financial results for the first quarter ended March 31, 2024. Individuals may participate in...

Karyopharm Announces Significant Refinancing Transactions and Amended Royalty Agreement Extending Vast Majority of Its Debt Maturities into 2028 and 2029 PR Newswire NEWTON, Mass., May 8, 2024 – $148.0 Million (86%) of Existing Convertible Notes due in 2025 to be Exchanged for $111.0 Million of New Convertible Notes due in 2029 and Warrants – – Issues New $100.0 Million Senior Secured Term Loan due in 2028 – – Repays Principal Portion and Amends Royalty Agreement with HealthCare...

Karyopharm Reports First Quarter 2024 Financial Results and Highlights Recent Company Progress PR Newswire NEWTON, Mass., May 8, 2024 – Announces Significant Refinancing Transactions and Amends Royalty Agreement with HealthCare Royalty Extending Vast Majority of Its Debt Maturities into 2028 and 2029, Well Beyond Expected Data Readouts and Potential Approvals from the Company's Three Phase 3 Trials, Strengthening the Company for its Next Stage of Growth – – Achieves First Quarter 2024...